Benzothiazine derivatives, their preparation and use

1. A benzothiazine derivative of Formula I

any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, wherein

R 1 represents hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl or heteroaryl; and

one of R 2 and R 3 represents hydrogen or alkyl other than t-butyl while the other of R 2 and R 3 represents cycloalkyl or cycloalkenyl; and

R 4 and R 5 , independently of each another, represent hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, and/or a saturated or partially saturated mono- or bi-cyclic heterocyclic ring; and

R 6 represents hydrogen, halogen, alkyl, cycloalkyl, haloalkyl or alkoxy; and

R 7 represents hydrogen, alkyl, cycloalkyl, hydroxyalkyl, alkenyl, alkynyl or halogen, or a group of the formula —R 10 —NR 9 R 8 , —R 10 —NO 2 , —R 10 —OR 8 , —R 10 —SR 8 , —R 10 —S(═O)NR 9 R 8 , —R 10 —S(═O)R 8 , —R 10 —S(═O) 2 R 8 , —R 10 —S(═O) 2 OR 8 , —R 10 —S(═O) 2 NR 9 R 8 , —R 10 —NR 9 S(═O) 2 R 8 , —R 10 —NR 11 S(═O) 2 NR 9 R 8 , —R 10 —CN, —R 10 —C(═NR 9 )R 8 , —R 10 —C(═NNR 9 )R 8 , —R 10 —C(═NOR 9 )R 8 , —R 10 —C(═O)R 8 , —R 10 —C(═O)NR 9 R 8 , —R 10 —C(═S)R 8 , —R 10 —C(═O)OR 8 , —R 10 —C(═S)OR 8 , —R 10 —C(═O)SR 8 , —R 10 —C(═S)SR 8 , —R 10 —C(═O)NR 9 (OR 8 ), —R 10 —C(═S)NR 9 (OR 8 ), —R 10 —C(═O)NR 9 (SR 8 ), —R 10 —C(═S)NR 9 (SR 8 ), —R 10 —CH(CN) 2 , —R 10 —C(═O)NR 9 R 8 , —R 10 —NR 9 C(═O)R 8 , —R 10 —NR 11 C(═O)NR 9 R 8 , —R 10 —C(═S)NR 9 R 8 , —R 10 —CH[C(═O)R 8 ] 2 , —R 10 —CH[C(═S)R 8 ] 2 , —R 10 —CH[C(═O)OR 8 ] 2 , —R 10 —CH[C(═S)OR 8 ] 2 , —R 10 —CH[C(═O)SR 8 ] 2 , —R 10 —CH[C(═S)SR 8 ] 2 , or —R 10 —CH[C(═S)NR 9 R 8 ] 2 ; wherein R 8 , R 9 and R 11 , independently of each another, represent hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, hydroxy, aryl or heteroaryl, which aryl or heteroaryl may optionally be substituted one or more times with alkyl, cycloalkyl, alkoxy, halogen, hydroxy, amino, trifluoromethyl, trifluoromethoxy or nitro; or R 8 and R 9 , together with the atoms to which they are bound, form a heterocyclic ring, which heterocyclic ring may optionally be substituted one or more times with alkyl, cycloalkyl, alkoxy, halogen, hydroxy, amino, trifluoromethyl, trifluoromethoxy or nitro, and R 11 is as defined above; and R 10 is absent or represents a linker selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl or heteroaryl; or R 7 represents a mono- or polycyclic carbocyclic or heterocyclic group, which carbocyclic or heterocyclic group may optionally be substituted one or more times with substituents selected from alkyl, cycloalkyl, hydroxyalkyl, alkenyl, alkynyl or halogen, or a group of the formula —R 10 —NR 9 R 8 , —R 10 —NO 2 , —R 10 —OR 8 , —R 10 —SR 8 , —R 10 —S(═O)NR 9 R 8 , —R 10 —S(═O)R 8 , —R 10 —S(═O) 2 R 8 , —R 10 —S(═O) 2 OR 8 , —R 10 —S(═O) 2 NR 9 R 8 , —R 10 —NR 9 S(═O) 2 R 8 , —R 10 —NR 11 S(═O) 2 NR 9 R 8 , —R 10 —CN, —R 10 —C(═NR 9 ) R 8 , —R 10 —C(═NNR 9 )R 8 , —R 10 —C(═NOR 9 )R 8 , —R 10 —C(═O)R 8 , —R 10 —C(═O)NR 9 R 8 , —R 10 —C(═S)R 8 , —R 10 —C(═O)OR 8 , —R 10 —C(═S)OR 8 , —R 10 —C(═O)SR 8 , —R 10 —C(═S)SR 8 , —R 10 C(═O)NR 9 (OR 8 ), —R 10 —C(═S)NR 9 (OR 8 ), —R 10 —C(═O)NR 9 (SR 8 ), —R 10 —C(═S)NR 9 (SR 8 ), —R 10 —CH(CN) 2 , —R 10 —C(═O)NR 9 R 8 , —R 10 —NR 9 C(═O)R 8 , —R 10 —NR 11 C(═O)NR 9 R 8 , —R 10 —C(═S)NR 9 R 8 , —R 10 —CH[C(═O)R 8 ] 2 , —R 10 —CH[C(═S)R 8 ] 2 , —R 10 —CH[C(═O)OR 8 ] 2 , —R 10 —CH[C(═S)OR 8 ] 2 , —R 10 —CH[C(═O)SR 8 ] 2 , —R 10 —CH[C(═S)SR 8 ] 2 , or —R 10 —CH[C(═S)NR 9 R 8 ] 2 ; wherein R 8 , R 9 and R 11 , independently of each another, represent hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, hydroxy, aryl or heteroaryl, which aryl or heteroaryl may optionally be substituted one or more times with alkyl, cycloalkyl, alkoxy, halogen, hydroxy, amino, trifluoromethyl, trifluoromethoxy or nitro; or R 8 and R 9 , together with the atoms to which they are bound, form a heterocyclic ring, which heterocyclic ring may optionally be substituted one or more times with alkyl, cycloalkyl, alkoxy, halogen, hydroxy, amino, trifluoromethyl, trifluoromethoxy or nitro, and R 11 is as defined above; and R 10 is absent or represents a linker selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl or heteroaryl.

2. The benzothiazine derivative of claim 1 , wherein R 1 represents hydrogen, alkyl or cycloalkyl.

3. The benzothiazine derivative of claim 1 , wherein R 1 represents hydrogen.

4. The benzothiazine derivative of claim 1 , wherein R 2 or R 3 represent cycloalkyl; and the other of R 2 and R 3 represent hydrogen.

5. The benzothiazine derivative of claim 1 , wherein R 4 or R 5 represent a saturated mono- or bi-cyclic heterocyclic ring having N, O and/or S as heteroatom.

6. The benzothiazine derivative of claim 5 , wherein R 4 or R 5 represent pyrrolidinyl, pyrazolidinyl, imidazolidinyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl.

7. The benzothiazine derivative of claim 1 , wherein R 4 and R 5 both represent hydrogen.

8. The benzothiazine derivative of claim 1 , wherein R 6 represents hydrogen or alkyl.

9. The benzothiazine derivative of any one of claims 1 , 2 , or 3 , wherein

R 7 represents —R 10 —S(═O) 2 R 8 , —R 10 —S(═O) 2 OR 8 , —R 10 —S(═O) 2 NR 9 R 8 , or —R 10 —NR 9 S(═O) 2 R 8 ; wherein

R 8 represents hydrogen or alkyl; and

R 9 represents hydrogen or alkyl; or

R 8 and R 9 together with the nitrogen and/or sulphur atoms to which they are bound, form a pyrrolidine-, a piperidine-, a piperazine-, a homopiperazine-, or a morpholine ring, which heterocyclic ring is optionally substituted with alkyl or hydroxy; and

R 10 is absent or represents alkyl.

10. The benzothiazine derivative of claim 9 , wherein R 7 represents

an N,N-dimethylamine-1-sulfonyl group;

a piperidine-1-sulfonyl group;

a 4-methyl-piperazine-1-sulfonyl group;

a morpholine-4-sulfonyl group; or

a 4-hydroxypiperidine-1-sulfonyl group.

11. The benzothiazine derivative of claim 1 , which is

(3RS)-3-Cyclohexyl-7-(piperidine-1-sulfonyl)-3,4-dihydro-2H-benzo[e][1,2]thiazine-1,1-dioxide;

(3RS)-3-Cyclopentyl-7-(piperidine-1-sulfonyl)-3,4-dihydro-2H-benzo[e][1,2]thiazine-1,1-dioxide;

(3RS)-3-Cyclopentyl-7-(4-methyl-piperazine-1-sulfonyl)-3,4-dihydro-2H-benzo[e][1,2]thiazine-1,1-dioxide;

(3RS)-3-Cyclohexyl-7-(4-methyl-piperazine-1-sulfonyl)-3,4-dihydro-2H-benzo[e][1,2]thiazine-1,1-dioxide;

(3RS)-3-Cyclopentyl-6-methyl-7-(piperidine-1-sulfonyl)-3,4-dihydro-2H-benzo[e][1,2]thiazine-1,1-dioxide;

(3RS)-3-Cyclopentyl-6-methyl-7-(morpholine-4-sulfonyl)-3,4-dihydro-2H-benzo[e][1,2]thiazine-1,1-dioxide;

(3RS)-3-Cyclopentyl-6-methyl-7-(4-methyl-piperazine-1-sulfonyl)-3,4-dihydro-2H-benzo[e][1,2]thiazine-1,1-dioxide;

(3RS)-3-Cyclopentyl-6-methyl-7-(N,N-dimethylamine-1-sulfonyl)-3,4-dihydro-2H-benzo[e][1,2]thiazine-1,1-dioxide;

(3RS)-3-Cyclopentyl-6-methyl-7-(4-hydroxypiperidine-1-sulfonyl)-3,4-dihydro-2H-benzo[e][1,2]thiazine-1,1-dioxide;

(3RS)-3-Cyclopentyl-7-(N,N-dimethylamine-1-sulfonyl)-3,4-dihydro-2H-benzo[e][1,2]thiazine-1,1-dioxide; or

(3RS)-3-Cyclopentyl-7-(morpholine-1-sulfonyl)-3,4-dihydro-2H-benzo[e][1,2]thiazine-1,1-dioxide;

or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition comprising a therapeutically effective amount of a benzothiazine derivative of claim 1 , or a pharmaceutically acceptable addition salt thereof, together with at least one pharmaceutically acceptable carrier or diluent.

13. The benzothiazine derivative of claim 11 , which is (3RS)-3-cyclopentyl-6-methyl-7-(4-methyl-piperazine-1-sulfonyl)-3,4-dihydro-2H-benzo[e][1,2]thiazine-1,1-dioxide.